Skip to content

Follow-up of SPTS in Patients With Raynaud's Phenomenon

Follow-up of Single-port Thoracoscopic Sympathicotomy in Patients With Raynaud's Phenomenon

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04015193
Enrollment
50
Registered
2019-07-10
Start date
2019-03-28
Completion date
2025-03-01
Last updated
2019-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Raynaud Phenomenon

Brief summary

Background: Raynaud's phenomenon is a vasospasm of the extremities, leading to extensive discomfort in daily life and potentially severe ischemia. Some patients are resistant to conventional vasodilatory drug treatment. In the University Medical Center Groningen, single-port thoracoscopic sympathicotomy (SPTS) was developed. This is a new minimally invasive endoscopic technique, extensively limiting surgical burden. In many hospitals in the Netherlands, this operation is sometimes performed on patients with Raynaud's phenomenon. However, the techniques used are more invasive than the SPTS technique. Furthermore, studies on sympathectomy and sympathicotomy in Raynaud's are limited and encompass obsolete more invasive techniques. Also, it is unclear which patients would benefit the most and for how long and in which percentage of patients treatment effects persist over time. In a recent study on the new SPTS technique, it was found that one month after the procedure, the Raynaud's attacks were substantially reduced and the hand perfusion increased on the operated side. Based on these short term effects and previously reported broad experience with this technique for other indications, it is possible to offer this option to a broader range of patients with Raynaud's as a reasonable and safe treatment option. However, whether the effects persist on the long-term needs to be established. Main research question: The aim of the study is to assess the 5 year efficacy and outcome in patients with primary and secondary Raynaud's phenomenon in whom SPTS has been performed. Design (including population, confounders/outcomes): Patients with Raynaud's, who will undergo SPTS in patient care setting, will be included. Data from the patient file will be collected, including vascular measurements to assess hand perfusion, a Raynaud diary (Raynaud condition score, duration and frequency of the attacks), quality of life questionnaires, and adverse events.

Interventions

PROCEDURESingle-port thoracoscopic sympathicotomy (patient care)

Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Raynaud's phenomenon of the hands * Scheduled SPTS as treatment for RP * Age ≥ 16 years

Exclusion criteria

• SPTS for other indications than RP

Design outcomes

Primary

MeasureTime frameDescription
Mean finger ischemia time5 yearMean finger ischemia time of five fingers during cooling and recovery, as assessed by routine cooling and recovery photo-electric plethysmography (PPG) after 5 years of follow-up, in minutes

Secondary

MeasureTime frameDescription
Mean finger ischemia time2 yearMean finger ischemia time of five fingers during cooling and recovery, as assessed by routine cooling and recovery photo-electric plethysmography (PPG) after 2 years of follow-up, in minutes
Raynaud Condition Score1,2,3,4,5 yearsMean Raynaud condition score (0-100) over a period 14 days
Number of attacks1,2,3,4,5 yearsMean number of RP attacks per day over a period of 14 days
Duration of attacks1,2,3,4,5 yearsMean duration of RP attacks per day over a period of 14 days in minutes
SF-361,2,3,4,5 yearsHealth-related quality of life short form (SF)-36 score of 100-0
HAQ1,2,3,4,5 years(Dutch) health assessment questionnaire (HAQ) score of 0-3
Capillary density2 and 5 yearsMean number of capillaries per finger of 8 fingers per 3mm
Number of dilated capillaries2 and 5 yearMean number of dilated capillaries per finger (apex width \>20µm, \<50µm) of 8 fingers per 3mm
Pulse wave velocity brachial-ulnar2 and 5 yearsPulse wave velocity in m/s of brachial-ulnar trajectory
Capillaroscopic pattern2 and 5 yearPattern of nailfold capillaries (normal, non-specific, early, active or late)
Pulse wave velocity brachial-radial2 and 5 yearsPulse wave velocity in m/s of brachial-radial trajectory
Systolic blood pressure2 and 5 yearsBrachial systolic blood pressure in mmHg
Diastolic blood pressure2 and 5 yearsBrachial diastolic blood pressure in mmHg
Mean finger blood pressure2 and 5 yearsMean finger blood pressure in mmHg of eight fingers
Digital ulcers1,2,3,4,5 yearsIncidence of digital ulcers (yes/no)
Compensatory sweating1,2,3,4,5 yearsCompensatory sweating (yes/no)
Wound infection or other adverse events2 weeks, 1,2,3,4,5 yearsOccurrence of wound infection or other adverse events potentially related to SPTS
Number of giant capillaries2 and 5 yearMean number of giant capillaries per finger (apex width \>50µm) of 8 fingers per 3mm

Countries

Netherlands

Contacts

Primary ContactDouwe J Mulder, MD, PhD
d.j.mulder@umcg.nl+31503612943

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026